← Human Trials & Peer-Reviewed Studies

The application of deconvolution analysis to elucidate the pulsatile nature of growth hormone secretion using a variable half-life of growth hormone.

Plain-language guide to PMID 2383925 (1990): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 10 subjects.

Key Facts

PMID
2383925
Journal
Clinical endocrinology
Year
1990
Study type
Randomized Controlled Trial
Authors
Hindmarsh PC et al. (5 authors)
DOI
10.1111/j.1365-2265.1990.tb00920.x

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

A deconvolution analysis model to calculate pituitary growth hormone (GH) secretion rate from measured serum GH concentration has been developed.

This uses an iterative method of 'curve-stripping' based on an estimate of the half-life.

Who Took Part

The abstract describes 10 subjects taking part.

The age groups tagged for this paper are teenagers and adults, men only.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

A deconvolution analysis model to calculate pituitary growth hormone (GH) secretion rate from measured serum GH concentration has been developed.

The subject headings attached to it are Growth Hormone, Half-Life and Models, Biological.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 10 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1990 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.